公开(公告)号：US20140004038A1

公开(公告)日：2014-01-02

申请号：US13708761

申请日：2012-12-07

Applicant: Genentech, Inc.

Inventor： Anan Chuntharapai ,  Gregory D. Plowman ,  Marc Tessier-Lavigne ,  Yan Wu ,  Weilan Ye

IPC: A61K39/395 ,  A61K45/06 ,  A61K51/10

CPC classification number: A61K39/3955 ,  A61K45/06 ,  A61K51/1093 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/22 ,  C07K16/2842 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/74

Abstract: The present invention relates to the use of VEGF antagonists and alpha5beta1 antagonists for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to use of a VEGFR agonists and alpha5beta1 agonists to promote angiogenesis and vascular permeability. The present invention also relates to new anti-alpha5beta1 antibodies, compositions and kits comprising them and methods of making and using them.

Abstract translation: 本发明涉及VEGF拮抗剂和α5β1拮抗剂用于治疗癌症并抑制血管生成和/或血管通透性的用途，包括抑制疾病中的异常血管发生。 本发明还涉及VEGFR激动剂和α5β1激动剂促进血管生成和血管通透性的用途。 本发明还涉及新的抗α5β1抗体，包含它们的组合物和试剂盒以及制备和使用它们的方法。